Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Operating Expenses (2022 - 2026)

Indivior Pharmaceuticals has reported Other Operating Expenses over the past 5 years, most recently at -$1.0 million for Q1 2026.

  • For Q1 2026, Other Operating Expenses changed 0.0% year-over-year to -$1.0 million; the TTM value through Mar 2026 reached -$3.0 million, up 98.47%, while the annual FY2025 figure was -$3.0 million, 98.46% up from the prior year.
  • Other Operating Expenses for Q1 2026 was -$1.0 million at Indivior Pharmaceuticals, up from -$2.0 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $6.0 million in Q4 2023 and troughed at -$299.0 million in Q4 2022.
  • A 5-year average of -$48.8 million and a median of -$1.0 million in 2022 define the central range for Other Operating Expenses.
  • Biggest five-year swings in Other Operating Expenses: surged 102.01% in 2023 and later tumbled 300.0% in 2025.
  • Year by year, Other Operating Expenses stood at -$299.0 million in 2022, then surged by 102.01% to $6.0 million in 2023, then tumbled by 83.33% to $1.0 million in 2024, then tumbled by 300.0% to -$2.0 million in 2025, then skyrocketed by 50.0% to -$1.0 million in 2026.
  • Business Quant data shows Other Operating Expenses for INDV at -$1.0 million in Q1 2026, -$2.0 million in Q4 2025, and -$1.0 million in Q1 2025.